

# Mechanism of the HDL<sub>2</sub> stimulation of progesterone secretion in cultured placental trophoblast

Miguel A. Lasunción,<sup>1</sup> Bartolomé Bonet, and Robert H. Knopp<sup>2</sup>

Northwest Lipid Research Clinic, and Department of Medicine, University of Washington, Seattle, WA 98104

**Abstract** Lipoprotein cholesterol (C) supports the high rate of progesterone production by the human placenta as endogenous cholesterol synthesis is low. To study underlying mechanisms whereby lipoproteins, including high density lipoprotein-2 (HDL<sub>2</sub>), stimulate progesterone secretion, trophoblast cells were isolated from human term placentas and maintained in primary tissue culture. Lipoproteins were added at several concentrations and medium progesterone secretion was determined. HDL<sub>2</sub> (d 1.063–1.125 g/ml) as well as low density lipoproteins (LDL) (d 1.019–1.063 g/ml) but not HDL<sub>3</sub> (d 1.125–1.21 g/ml) stimulated progesterone secretion in a dose-dependent manner, with HDL<sub>2</sub> cholesterol entering the cell and serving as substrate for progesterone synthesis. Conversely, LDL and HDL<sub>2</sub> produced a significant decrease in [<sup>14</sup>C]acetate incorporation into cell cholesterol. Cholesterol-depleted lipoproteins did not stimulate progesterone secretion. The stimulating effect of LDL was abolished by apolipoprotein modification by cyclohexanedione or reductive methylation and by the addition of anti-LDL receptor antibody or 10 μM chloroquine to the medium. [<sup>14</sup>C]acetate conversion into cholesterol was accelerated by these procedures. However, HDL<sub>2</sub> stimulation of progesterone secretion and reduction of [<sup>14</sup>C]acetate incorporation into cholesterol was not blocked by chemical modification of apolipoproteins, anti-LDL receptor antibody, or chloroquine. Treatment of HDL<sub>2</sub> with tetranitromethane or dimethylsuberimide also did not block the stimulation of progesterone. To determine whether the capacity of HDL<sub>2</sub> to deliver cholesterol to the trophoblast cells was restricted to subfractions differing in apoE content, HDL<sub>2</sub> was chromatographed on heparin-Sepharose and three fractions (A, B, and C) were obtained. Fraction A was poorest in apoE and free cholesterol, fraction B contained the majority of cholesterol, and fraction C was the richest in apoE and free cholesterol. When added to trophoblast cells, fraction A stimulated little progesterone secretion, fraction B stimulated moderately, and fraction C did so greatly. Modification of these subfractions with cyclohexanedione or reductive methylation did not inhibit these effects. ■ In conclusion, HDL<sub>2</sub> stimulated progesterone secretion in human trophoblast cell culture. Contrary to LDL, the HDL effect was not mediated by apolipoproteins or the LDL receptor pathway. The ability of HDL<sub>2</sub> to stimulate progesterone secretion is consistent with the passive transfer of free cholesterol to the cell membrane from a physicochemically specific subfraction of HDL. This mechanism may be an auxiliary source of cholesterol for human steroidogenic cells. — **Lasunción, M. A., B. Bonet, and R. H. Knopp.** Mechanism of the HDL<sub>2</sub> stimulation of progesterone secretion in cultured placental trophoblast. *J. Lipid Res.* 1991. 32: 1073–1087.

**Supplementary key words** low density lipoprotein • free cholesterol • apolipoprotein

The human placenta manufactures approximately 400 mg of sex steroids daily (1). Since much of this steroid hormone is derived from plasma cholesterol (2) and little cholesterol is manufactured by the placenta itself (3), the mechanism of transfer of lipoprotein cholesterol to the placenta is of great biological interest. Low density lipoprotein (LDL<sub>2</sub>) is a major donor of cholesterol to cells via the LDL receptor (for review, see ref. 4). The LDL pathway has been demonstrated in human trophoblastic cells in primary culture by Winkel et al. (5–7). Binding of <sup>125</sup>I-labeled LDL to trophoblastic cells is mediated by high affinity, low capacity specific receptors (7, 8) and LDL stimulates progesterone secretion (5). While specific binding capacity of trophoblastic membrane preparations for <sup>125</sup>I-labeled HDL<sub>3</sub> was much greater than for LDL (8), stimulation of progesterone secretion by HDL<sub>3</sub> (d 1.125–1.215 g/ml) was less than by LDL (5). The HDL<sub>2</sub> fraction (d 1.063–1.125 g/ml) was not examined. The conclusion was drawn from these studies that placental biosynthesis of progesterone was principally dependent on cholesterol derived from maternal LDL (5).

More recently, we observed that cultured human trophoblast secretes as much or more progesterone in response to HDL<sub>2</sub> than to LDL<sub>2</sub> when cells are incubated

Abbreviations: LDL, low density lipoproteins; LDL<sub>2</sub>, low density lipoproteins d 1.019–1.063 g/ml; HDL, high density lipoproteins; HDL<sub>2</sub>, high density lipoproteins d 1.063–1.125 g/ml; HDL<sub>3</sub>, high density lipoproteins d 1.125–1.215 g/ml; TNM, tetranitromethane; DMS, dimethylsuberimide; FBS, fetal bovine serum; LPPS, lipoprotein-poor fetal bovine serum; CE, cholesteryl ester; [<sup>3</sup>H]CE-HDL<sub>2</sub>, HDL<sub>2</sub> labeled with [<sup>3</sup>H]CE; TLC, thin-layer chromatography.

<sup>1</sup>Present address: Servicio de Bioquímica-Investigación, Hospital Ramón y Cajal, Madrid, Spain.

<sup>2</sup>To whom reprint requests should be addressed at: NW Lipid Research Clinic, ZA-36, 326 Ninth Avenue, Seattle, WA 98104.

at equal concentrations of lipoprotein cholesterol (9, 10). Evidence for HDL<sub>2</sub> delivery of cholesterol to human non-endocrine cells has also been obtained both in the presence and absence of apoE (11, 12). Since apoE competes efficiently with apoB-100 for the LDL receptor (13), the HDL<sub>2</sub> stimulation of progesterone secretion by trophoblast may be due to the presence of apoE in HDL<sub>2</sub>, which would then be taken up by cells through the LDL receptor. Alternatively, a distinct apoE receptor that recognizes apoE but not apoB has been described in dog liver (14) and could be present in placenta as well. Another HDL receptor that likely binds apoA-I has been reported in human fibroblasts, arterial smooth muscle cells, endothelial cells, and macrophages (15–17) and is associated with increased binding of HDL<sub>3</sub> when cell cholesterol concentrations are high and with diminished binding when cell cholesterol concentrations are low (18, 19). The chemical nature of this binding site is still controversial (20–22), however a protein that binds apoA-I has been recently purified from human placenta (23). It is not known whether these binding relationships apply to HDL<sub>2</sub>.

The purpose of the present work is to determine the mechanism involved in the uptake and utilization of HDL<sub>2</sub> cholesterol by human trophoblast in primary culture. The results demonstrate that HDL<sub>2</sub>-stimulated progesterone secretion is associated with apoE-rich subclasses, but that the process is not inhibited as expected by chemical modification of apolipoproteins E and A-I in HDL<sub>2</sub> or by anti-LDL receptor antibody or chloroquine, while the effect of LDL in stimulating progesterone secretion is inhibited as expected by chemical modification of apoB, anti-LDL antibody, and chloroquine. These results suggest a physicochemical specificity for lipoprotein delivery of cholesterol to cells for steroidogenesis that is independent of the B/E receptor and apolipoprotein-mediated binding of HDL to cell membranes.

## MATERIALS AND METHODS

### Trophoblast isolation and incubation

Two isolation procedures were used. In the first, human term placentas from women undergoing elective caesarian section were used, according to Winkel et al. (5). Fetal cotyledons were dissected and rinsed repeatedly in sterile 0.15 M NaCl. The trophoblastic tissue was teased carefully from the fibrous tissue and the vascular stroma under a sterile UV or laminar flow hood. In a sterile Erlenmeyer flask, the trophoblast was mixed with 50 ml of HAM's F-10 medium (GIBCO, Grand Island, NY) containing 0.25% trypsin (GIBCO) and deoxyribonuclease I (Sigma, St. Louis, MO) and incubated at 37°C in a shaking water bath. After 20 min, the supernatants containing red blood cells and other damaged cells were discarded. The process was repeated twice and these supernatants, now contain-

ing largely the trophoblast cells, were poured off over 5 ml of fetal bovine serum (GIBCO) and kept on ice. After filtration through sterile gauze and centrifugation at 800 rpm for 5 min, the cell pellets were combined, suspended in lysing buffer, and incubated on ice for 10 min (5). The cells were collected by centrifugation over 1 ml fetal bovine serum (FBS) and brought to the desired volume with HAM's F-10 medium, pH 7.4, containing 10% FBS, 50 µg/ml penicillin, 50 µg/ml streptomycin, 100 µg/ml neomycin, and 2.5 ng/ml fungizone (GIBCO). In later experiments, trophoblast cells were obtained by digesting the minced tissue at 37°C for 60 min in buffered HAM's F-10 medium containing 100 IU/ml collagenase type II (Worthington Biochemical Corp., Freehold, NJ), 0.2 mg/ml hyaluronidase (Sigma), 0.004 mg/ml deoxyribonuclease I (Sigma), and 2% fetal bovine serum (GIBCO). The cell suspension was filtered through sterile gauze, pelleted by low speed centrifugation, and the cells were resuspended in plain HAM's F-10 medium. The trophoblast cells were separated from red cells and macrophages distinguished by immunocytochemical stains (Bonet, B., A. Gown, J. B. Brunzell, and R. H. Knopp, manuscript submitted) by isopycnic centrifugation on linear gradients of 40% Percoll (Pharmacia Fine Chemicals, Uppsala, Sweden). Cells with densities of 1.01–1.02 g/ml were pooled, washed several times to eliminate Percoll, and resuspended in a small volume of HAM's F-10 medium containing 10% fetal bovine serum and the antibiotic mixture as above.

In both isolation procedures, cell number and viability were determined by trypan blue exclusion. Cells were plated in 24-well culture plates (Falcon Primaria, Becton Dickinson, Lincoln Park, NJ) at a rate of 10<sup>6</sup> cells/well. Basal progesterone secretion and also the magnitude of the response to lipoproteins varied among the experiments, which is related to the cell preparation rather than to lipoproteins.

### Lipoprotein isolation and modification

Plasma was obtained from fasted healthy volunteers. Lipoproteins were isolated according to the sequential ultracentrifugation technique (24) in the following ranges: LDL<sub>2</sub> (d 1.019–1.063 g/ml), HDL<sub>2</sub> (d 1.063–1.125 g/ml), and HDL<sub>3</sub> (d 1.125–1.215 g/ml), in a Beckman L5-50 ultracentrifuge. Each fraction was recentrifuged for 24 h at the appropriate density to minimize albumin contamination. The lipoproteins were exhaustively dialyzed against 0.15 M NaCl, 1 mM Na<sub>2</sub>EDTA, pH 7.4, for 24 h before use in tissue culture experiments. Cholesterol-depleted lipoproteins were prepared by hexane washing (25).

For incubation, 2-ml aliquots of cell suspensions were plated on Linbro 3.5 × 1 cm multiwell plates (VWR Scientific Co., Media, PA) and maintained at 37°C in a humidified 5% CO<sub>2</sub>, 95% air environment. After a 16-h

period to allow the trophoblast cells to adhere to the culture dish, media were changed to HAM's F-10 containing 10% lipoprotein-poor fetal bovine serum (LPPS). Cells were incubated in this medium prior to addition of lipoproteins and the media were changed every 24 h. All media changes and additions were performed under a UV hood or laminar flow hood. Lipoproteins were added at the cholesterol concentration specified in the text for every experiment in the 10% LPPS media containing the antibiotic mixture and fungizone mentioned above. [2-<sup>14</sup>C]acetate (51 mCi/mmol, New England Nuclear, Boston, MA) was added to media at the final concentration of 20 μM. After a 24-h incubation in the presence of the lipoproteins (or in their absence for the control), the media were collected and the cells were washed twice with 2 ml of 0.15 M NaCl. The cells were collected and extracted according to the procedure of Oram, Albers, and Bierman (26). In later experiments when trophoblasts were incubated with [<sup>3</sup>H]CE-HDL<sub>2</sub>, cells were grown in AIM-5 medium (GIBCO).

#### Cyclohexanedione modification of lipoproteins

The procedure of Mahley et al. (13) was followed. In brief, one volume of lipoprotein solution (ca. 5 mg protein/ml) in 0.15 M NaCl was mixed with two volumes of 0.15 M 1,2 cyclohexanedione (Sigma) in 0.2 M sodium borate buffer (pH 8.1) and incubated for 2 h at 37°C. The samples were then exhaustively dialyzed against buffered 0.15 M NaCl, 1 mM Na<sub>2</sub>EDTA, pH 7.4. The success in the modification was assessed by agarose gel electrophoresis (Paragon, Beckman, Palo Alto, CA).

#### Reductive methylation of lipoproteins

Using the procedure of Weisgraber, Innerarity, and Mahley (27), the lipoprotein solutions (ca. 5 mg protein/ml) in 0.15 M NaCl were diluted 1:2.5 with 0.3 M sodium borate buffer, pH 9.0, and placed on an ice bath. For every 5 mg of lipoprotein protein, 1 mg of sodium borohydride was added to the solution at zero time and at 30 min thereafter, with concomitant additions of 1 μl of 37% formaldehyde every 6 min over 60 min. The samples were then chromatographed on Sephadex B-50 to stop the reaction, and the fractions containing the lipoproteins were dialyzed against buffered 0.15 M NaCl, 1 mM Na<sub>2</sub>EDTA, pH 7.4, and used within the following 5 days.

#### Tetranitromethane modification of lipoproteins

The method of Chacko (28) and Chacko et al. (29) was followed. Tetranitromethane (TNM) was dissolved in 95% ethanol and added to the HDL solution (2 mg protein/ml) at a rate of 3 μmol TNM/mg HDL protein. The mixture was allowed to stand for 1 h at room temperature and dialyzed in the cold against buffered 0.15 M NaCl, 1 mM Na<sub>2</sub>EDTA, pH 7.4.

#### Dimethylsuberimidate modification of lipoproteins

One ml of HDL<sub>2</sub> solution (5 mg protein) was mixed with 0.1 ml of 1 M triethanolamine-HCl buffer, pH 9.5, and 5 mg of dimethylsuberimidate (DMS) according to Chacko, Mahlberg, and Johnson (30). After incubation for 2 h at room temperature, the samples were exhaustively dialyzed against buffered 0.15 M NaCl, 1 mM Na<sub>2</sub>EDTA, pH 7.4.

#### Heparin-Sepharose chromatography for HDL<sub>2</sub> subfractionation

Heparin-Sepharose CL-6B was purchased from Pharmacia Fine Chemicals AB and packed in a 1.5 × 25 cm glass column. The elution pattern used was that described by Weisgraber and Mahley (31). The heparin-Sepharose was equilibrated at 4°C with 0.05 M NaCl, 0.005 M Tris, 0.025 M MnCl<sub>2</sub>, pH 7.4. The samples were dissolved in this buffer, loaded onto the column, and after equilibration overnight the same buffer was infused at a rate of 23 ml/h and 3.4-ml fractions were collected. After the first peak was eluted, the buffer was changed to 0.095 M NaCl, 0.005 M Tris, pH 7.4, without manganese for the elution of a second peak. A final increase in the NaCl concentration of the eluent to 0.29 M led to the collection of a third peak. Absorption at 280 nm was monitored and the fractions were appropriately combined and dialyzed against 0.15 M NaCl, 1 mM Na<sub>2</sub>EDTA, pH 7.4. The recovery of protein applied to the column in six runs was 88 ± 4% and that of cholesterol 85 ± 4%.

#### Labeling HDL<sub>2</sub>-CE

HDL<sub>2</sub> was labeled with [<sup>3</sup>H]cholesteryl ester ([<sup>3</sup>H]CE), adding 50 μCi dissolved in 150 μl of ethanol and 1 ml of a solution containing partially purified lipid transfer protein to the HDL<sub>2</sub> solution. This mixture was incubated at 37°C overnight and reisolated by ultracentrifugation at 40,000 rpm for 20 h. With this procedure, the [<sup>3</sup>H]CE-HDL<sub>2</sub> was isolated at the bottom of the tube from the rest of the [<sup>3</sup>H]CE in the top. About 60% of the total amount of [<sup>3</sup>H]CE was incorporated into HDL<sub>2</sub>. In HDL, about 75% of the label was present as cholesteryl ester and 25% as free cholesterol in several experiments, even though the starting labeled cholesterol was 99.7% esterified or more as judged by thin-layer chromatography.

#### Incubation of trophoblasts with [<sup>3</sup>H]CE-HDL<sub>2</sub>

Trophoblasts from human placenta were incubated with AIM-5 medium for 24 h. Medium was then removed and 1 ml of fresh medium containing [<sup>3</sup>H]CE-HDL<sub>2</sub> (sp act 28 cpm/ng cholesterol) was added. Cells were incubated for 24 or 48 h. The medium was removed and the cells were washed 5 times with cold saline. The same process was done in wells with no cells. Lipid extraction

was as described by Hara and Radin (32). The samples were dried under N<sub>2</sub> and redissolved with 125 μl of chloroform. Fifty μl of this solution was used for the thin-layer chromatography (33). Two eluants were used for the TLC, one using petroleum ether–diethyl ether–acetic acid 70:30:1 (v/v/v) that separates cholesteryl esters and a second using the same components at 70:30:2 (v/v/v) that separates free cholesterol and progesterone. The same procedure was done for wells containing no cells and the counts obtained were subtracted from those obtained in wells containing cells.

### Analyses

Progesterone was measured in the media by radioimmunoassay using a commercial “coated tube” kit (Diagnostic Products Corp., Los Angeles, CA). Cells were extracted in chloroform–methanol (34) and protein was measured by the method of Lowry et al. (35). The lipid extract was saponified and the nonsaponifiable lipids were extracted in hexane (36), resuspended in isopropanol, and the cholesterol was precipitated with digitonin (37). <sup>14</sup>C-radioactivity was determined using a TriCarb 460C Packard liquid scintillation spectrometer. Some culture media were extracted with chloroform–methanol (34) and processed as mentioned for the cells. Assays of cellular free and esterified cholesterol were performed using the enzymatic fluorimetric method of Heider and Boyett (38) before and after saponification.

Total and free cholesterol contents in lipoproteins were measured by commercial enzymatic kits (Sigma). Lipoprotein protein was measured by the method of Lowry et al. (35). SDS electrophoresis was performed on 10% polyacrylamide gels using phosphate buffer as eluant (39) on a Pharmacia Gel Electrophoresis Apparatus GE-4LS. For determining the apparent molecular weight of the lipoproteins, PAA 4/30 gradient gels (Pharmacia Fine Chemicals) were used according to the instructions of the manufacturer. After electrophoresis, the gels were stained with 0.04% Coomassie G-250 in 0.05% perchloric acid. Apolipoprotein immunoassays were performed as described for apoA-I (40), apoA-II (41), apoD (42), and apoE (43).

Results are expressed as mean ± SE. Mean differences between groups were tested by Student's *t*-paired test and by the multiple range analysis (*t*-Tukey) using the statistical program, Statgraphics (Statistical Graphics Corp., Princeton, NJ).

## RESULTS

### Effect of lipoprotein subfractions on progesterone secretion and cell cholesterol content

The addition of increasing amounts of HDL<sub>2</sub> to trophoblast cells in culture produced a dose-dependent in-

crease in the amount of progesterone secreted into the medium (Fig. 1) that was clearly detectable at medium cholesterol concentrations of 10 mg/dl. To determine whether lipoprotein-induced increases in progesterone secretion were associated with changes in the amount of trophoblast free and esterified cholesterol, concentrations of these parameters were measured without and with lipoprotein additions in studies in which endogenous cholesterol synthesis was inhibited with compactin. Results are presented in Table 1 and show that the concentrations of free and esterified cholesterol and the amount of progesterone secreted are higher in the presence of added LDL<sub>2</sub> or HDL<sub>2</sub> but free cholesterol and progesterone are lower in the presence of HDL<sub>3</sub>.

To show that HDL<sub>2</sub> can physically provide cholesterol for progesterone synthesis, trophoblasts were incubated for 24 or 48 h with a medium containing [<sup>3</sup>H]CE-HDL<sub>2</sub>. Total lipid extraction of the cells showed an incorporation of ~2% of the total amount of cholesterol added in the medium. On TLC, most of the cellular <sup>3</sup>H was present as free cholesterol and less as cholesteryl ester (Table 2). At the end of the incubation, the majority of the [<sup>3</sup>H]cholesterol in the medium (60–80%) remained in the form of esterified cholesterol. Incorporation of [<sup>3</sup>H]cholesterol into progesterone was consistent and reproducible in the three experiments.

To obtain further evidence that LDL<sub>2</sub> and HDL<sub>2</sub> cholesterol influences progesterone secretion, lipoproteins depleted of cholesterol by hexane washing were added to trophoblast cultures and progesterone secretion was measured. In this experiment all lipoproteins were added at equal protein concentrations. The cholesterol depletion procedure completely removed cholesterol from LDL<sub>2</sub>,




Fig. 1. Effect of HDL<sub>2</sub> on progesterone secretion by trophoblast cells in culture. Trophoblast cells (ca. 10<sup>6</sup> cells/well) were incubated in HAM's F-10 medium containing 10% lipoprotein-poor serum for 48 h and then for 24 h in the same medium supplemented with increasing amounts of HDL<sub>2</sub>. Progesterone in the medium was determined and the data were expressed as the percent of the value observed under basal conditions (absence of lipoprotein cholesterol). Values correspond to the mean of two independent experiments in which basal progesterone levels were 2.5 and 11 ng/well, respectively.

TABLE 1. Effect of lipoprotein additions on trophoblast cholesterol content and progesterone secretion

Addition	Cholesterol		Progesterone
	Free	Esterified	
	$\mu\text{g}/\text{mg protein}$		$\text{ng}/\text{mg protein}$
LPPS + compactin <sup>a</sup>	15 ± 1	4 ± 1	131 ± 40
LPPS + LDL <sub>2</sub>	24 ± 2	11	218 ± 88
LPPS + HDL <sub>2</sub>	27 ± 11	15 ± 5	262 ± 108
LPPS + HDL <sub>3</sub>	9 ± 1	17 ± 2	84 ± 68

Cultures were incubated for 24 h in 10% fetal calf serum. The effects of experimental additions were observed over the next 24 h. Compactin was added at a concentration of 0.5  $\mu\text{M}$ . Values are given as mean ± SE of two or three observations.

<sup>a</sup>Compactin was present in all conditions. Lipoproteins were added at 35 mg/dl cholesterol.

achieved a 45% reduction in HDL<sub>2</sub> cholesterol, but had little effect on HDL<sub>3</sub> (Table 3). Unmodified LDL<sub>2</sub> and HDL<sub>2</sub> stimulated progesterone secretion, but less progesterone was secreted in the HDL<sub>2</sub> compared to LDL<sub>2</sub>, possibly due to the fact that HDL was added at a lower cholesterol concentration than LDL<sub>2</sub>. In the case of cholesterol-depleted LDL<sub>2</sub> and HDL<sub>2</sub> progesterone secretion was reduced to below LPPS control levels. In the presence of HDL<sub>3</sub>, progesterone secretion was again reduced below LPPS control. There was no difference between unmodified versus treated HDL<sub>3</sub> on inhibiting progesterone secretion. None of the treatments appreciably altered the cell protein concentrations (Table 3).

#### Effect of chemical modification of the lipoproteins

To determine whether endocytosis by the LDL receptor or binding to the HDL receptor were involved in the utilization of HDL<sub>2</sub>-cholesterol for progesterone secretion, human trophoblast cells were incubated for 24 h in the presence of native and modified LDL, HDL<sub>2</sub>, and HDL<sub>3</sub> at two cholesterol concentrations in the media (5 and 20 mg cholesterol/dl). Results illustrated in Fig. 2 cor-

respond to a representative experiment out of the three performed that gave similar results. Results of progesterone secretion in 24 h are expressed as a percent of basal. As shown in Fig. 2, native LDL and HDL<sub>2</sub> both stimulated progesterone secretion in a dose-dependent manner, and the values reached were similar with both lipoprotein preparations. In contrast, native HDL<sub>3</sub> did not stimulate progesterone secretion at any of the studied lipoprotein concentrations.

Four different procedures were used to determine whether apolipoproteins had a specific role in stimulating progesterone secretion. Cyclohexanedione modification and reductive methylation were used to inhibit lipoprotein interaction with the LDL receptor mediated by either apoB-100 or apoE, and TNM and DMS modifications were used to inhibit binding to the putative HDL receptor. The conditions used for lipoprotein modification with cyclohexanedione and reductive methylation (which modify arginine and lysine, respectively) were those known to inhibit the binding of either apoB-100 or apoE to the fibroblast LDL receptor more than 90% (13, 27). All cyclohexanedione-modified lipoproteins (LDL<sub>2</sub> or HDL<sub>2</sub>) showed a faster mobility in agarose electrophoresis than their respective native forms (data not shown). The extent of the reductive methylation modification was not further studied.

As shown in Fig. 2, modification of LDL<sub>2</sub> by cyclohexanedione or reductive methylation reduced progesterone secretion as compared to native LDL<sub>2</sub> such that progesterone secretion was no longer different from that observed under basal conditions. On the other hand, modification of HDL<sub>2</sub> by cyclohexanedione or reductive methylation did not affect progesterone secretion and the values observed were always significantly higher than those in the control wells.

In order to cross-link their apolipoproteins and phospholipids, HDL<sub>2</sub> and HDL<sub>3</sub> were separately modified by TNM treatment (28, 29) and HDL<sub>2</sub> also by DMS (30). The conditions used for these modifications were those

TABLE 2. Uptake of [<sup>3</sup>H]cholesterol from HDL<sub>2</sub> by trophoblast and incorporation into progesterone

Experiment	Total Lipid Extraction	Free Cholesterol	Cholesteryl Esters	Progesterone
	$\mu\text{g}/\text{mg cell protein}$			
Exp. 1				
24 h	3.68 ± 0.2	2.6 ± 0.2		0.018 ± 0.005
48 h	4.75 ± 1.3	3.5 ± 0.5	0.28 ± 0.02	0.018 ± 0.003
Exp. 2				
24 h	5.04 ± 0.31	2.37 ± 0.5	0.34 ± 0.08	0.020 ± 0.002
48 h	6.80 ± 0.66	2.81 ± 0.28	0.99 ± 0.11	0.023 ± 0.002
Exp. 3				
24 h	3.74 ± 0.41	2.83 ± 0.61	0.52 ± 0.22	0.027 ± 0.01
48 h		3.10 ± 0.38	0.59 ± 0.06	0.024 ± 0.009

Trophoblasts were incubated with 60  $\mu\text{g}$  of [<sup>3</sup>H]CE-HDL<sub>2</sub> (sp act 29 cpm/mg of cholesterol) for 24 or 48 h. Values are given as mean ± SE of three different wells per experiment.

TABLE 3. Effect of removing cholesterol from LDL<sub>2</sub>, HDL<sub>2</sub>, and HDL<sub>3</sub> on trophoblast progesterone secretion

Addition	Hexane Washing <sup>a</sup>	Lipoprotein Cholesterol <sup>b</sup>	Medium Progesterone	Cell Protein
		mg/dl	ng/well	µg/well
LPPS	-	ND	34.8 ± 3.1 <sup>c</sup>	198 ± 11
LDL <sub>2</sub>	-	22.8	51.8 ± 3.0	186 ± 5
LDL <sub>2</sub>	+	ND	25.2 ± 2.9	179 ± 9
HDL <sub>2</sub>	-	6.5	43.5 ± 3.5	216 ± 5
HDL <sub>2</sub>	+	3.6	24.8 ± 1.7	188 ± 18
HDL <sub>3</sub>	-	2.2	18.0 ± 1.3	184 ± 3
HDL <sub>3</sub>	+	1.9	21.2 ± 2.9	177 ± 1

Trophoblast cells were incubated for 48 h in LPPS before additions; ND, nondetectable.

<sup>a</sup>Cholesterol was removed from cells by hexane washing (25).

<sup>b</sup>All lipoproteins were incubated at an equal lipoprotein protein concentration of 15 mg/dl (150 µg/ml).

<sup>c</sup>Mean ± SE of three incubations.

known to block the ability of HDL<sub>3</sub> to interact with rat liver or human fibroblast membranes (28-30). TNM-modified HDL<sub>2</sub> and HDL<sub>3</sub> migrated as a broad band and more anodally than native forms in agarose electrophoresis and showed a slower migration in 3-40% polyacrylamide gradient gel electrophoresis, suggesting the presence of particle aggregation in the modified lipoprotein preparations (data not shown). On the other hand, DMS-HDL<sub>2</sub> showed very increased mobility in agarose electrophoresis as compared to native HDL<sub>2</sub> (results not shown).

As also shown in Fig. 2, modification of HDL<sub>2</sub> with TNM or DMS did not affect progesterone secretion as compared to native HDL<sub>2</sub> at either of the cholesterol concentrations in the media, and progesterone secretion observed in the presence of the modified HDL<sub>2</sub> was significantly higher than in the absence of lipoproteins. Likewise, TNM-modified HDL<sub>3</sub> behaved similarly to native HDL<sub>3</sub>, the secretion of progesterone in the presence of either modified or native HDL<sub>3</sub> being no different from that observed under basal conditions (Fig. 2).

In another set of experiments, the effect of lipoproteins on the incorporation of [<sup>14</sup>C]acetate into cholesterol by trophoblast was studied. As shown in Fig. 3, native LDL as well as HDL<sub>2</sub> produced a reduction in the appearance of [<sup>14</sup>C]cholesterol in cells as compared to controls, which is consistent with the stimulation of progesterone secretion seen above. The modification of LDL with either cyclohexanedione or reductive methylation led to a significant increase in [<sup>14</sup>C]cholesterol appearance as compared to native LDL. In contrast, chemical modification of HDL<sub>2</sub> by these procedures did not produce any change in [<sup>14</sup>C]acetate incorporation into cell cholesterol, consistent with the divergent effects of chemical modification of LDL versus HDL<sub>2</sub> on progesterone secretion.

#### Effects of anti-LDL receptor antibody and chloroquine

To confirm that the effect of LDL but not that of HDL<sub>2</sub> was mediated by the uptake of the lipoprotein particle by a receptor-mediated mechanism, human trophoblast cells





Fig. 2. Effects of cyclohexanedione, reductive methylation, tetranitromethane, and dimethylsuberimidate modification of LDL, HDL<sub>2</sub>, and HDL<sub>3</sub> on progesterone secretion by the trophoblast cells in culture. Trophoblast cells (10<sup>6</sup> cells/well) were incubated in HAM's F-10 medium containing 10% lipoprotein-poor serum for 48 h and then for 24 h in the same medium supplemented with 5 (open bars) or 20 (dashed bars) mg/dl of lipoprotein cholesterol. Progesterone in the medium was determined by radioimmunoassay and the data were expressed as the percent of the value observed under basal conditions (absence of lipoprotein cholesterol). Values correspond to the mean ± SE of triplicate incubations from one experiment out of three performed that gave similar results. Progesterone secretion in basal conditions was 12.2 ± 0.4 ng/well. N, native; Cy, cyclohexanedione; RM, reductive methylation; TNM, tetranitromethane; DMS, dimethylsuberimidate. Statistical comparisons between modified and native lipoproteins were performed by the multiple range analysis (*t*-Tukey): \* = *P* < 0.05; \*\* = *P* < 0.01.


**Fig. 3.** Effects of cyclohexanedione and reductive methylation modification of LDL and HDL<sub>2</sub> on [<sup>14</sup>C]cholesterol production by trophoblast cells in culture. Trophoblast cells (10<sup>6</sup> cells/well) were incubated in HAMS's F-10 medium containing 10% lipoprotein-poor serum for 48 h and then for 24 h in the same medium supplemented with 20 μM [2-<sup>14</sup>C]acetate and 40 mg/dl lipoprotein-cholesterol. [<sup>14</sup>C]cholesterol was determined by digitonin precipitation of an extract of cell lipids. Results are expressed as the percent of the value observed under basal conditions (absence of lipoprotein cholesterol). Each value corresponds to the mean of the triplicate incubations; native, native lipoproteins; modified, modified lipoproteins. Open circles (○) indicate experiments with cyclohexanedione-modified lipoproteins; solid circles (●) indicate experiments with reductive methylation-modified lipoproteins. Statistical comparison between modified and native lipoproteins was done by the *t*-paired test; NS, not significant, *P* > 0.05.



were incubated for 24 h with 20 mg/dl of lipoprotein cholesterol in the presence or the absence of either anti-LDL receptor antibody or chloroquine, and progesterone secretion was determined. Monoclonal anti-LDL receptor antibody was generously provided by Dr. Alan Chait. As in previous experiments, both LDL and HDL<sub>2</sub> stimulated progesterone secretion as compared to basal incubations (absence of lipoprotein-cholesterol) (Fig. 4). The addition of anti-LDL receptor antibody or chloroquine to the con-

trol wells did not cause any significant effect (data not shown). When these agents were added to wells containing LDL, a significant decrease in progesterone secretion was observed. In fact, in the presence of the anti-LDL receptor antibody, LDL did not significantly stimulate progesterone secretion as compared to basal incubation. In contrast, neither the anti-LDL receptor antibody nor chloroquine modified the effect of HDL<sub>2</sub> stimulating progesterone secretion (Fig. 4).

#### PROGESTERONE SECRETION



**Fig. 4.** Effects of anti-LDL receptor antibody and 10 μM chloroquine on progesterone secretion stimulated by LDL and HDL<sub>2</sub>. Trophoblast cells (10<sup>6</sup> cells/well) were incubated in HAM's F-10 medium for 48 h and then for 24 h in the same medium supplemented with 20 mg/dl lipoprotein cholesterol and either monoclonal anti-LDL receptor antibody or 10 μM chloroquine, and progesterone in medium was determined. The results are expressed as the percent of the value observed under basal conditions (in the absence of lipoprotein cholesterol), which was 29.2 ± 2.1 ng/well. Values correspond to the mean ± SE of six wells from two independent experiments. Statistical comparisons between the presence versus the absence of anti-LDL receptor antibody or chloroquine were done by the multiple range analysis (*t*-Tukey); • = *P* < 0.05; \*\*\* = *P* < 0.001.

## Characteristics of HDL<sub>2</sub> separated by heparin-Sepharose affinity chromatography

Although inactivation of apoB-100 and apoE by chemical modification did not inhibit the effect of HDL<sub>2</sub> on steroidogenesis, the apoE content of HDL might still be associated with the HDL<sub>2</sub> effect in some way. To investigate the effect of HDL<sub>2</sub> rich or poor in apoE, HDL<sub>2</sub> was chromatographed on a heparin-Sepharose column in order to separate fractions containing different amounts of apoE (31). HDL<sub>2</sub> from three normolipidemic donors (two females not using birth control pills CL and KP, and one male, MAL) were subfractionated twice each, with high reproducibility. Fig. 5 illustrates the elution profile for each HDL<sub>2</sub> preparation. Sequential elution with three solutions of increasing NaCl concentration yielded three separate peaks. The first peak was eluted with a 0.05 M NaCl, 0.025 M MnCl<sub>2</sub>, buffered solution and corresponds to the unbound fraction (fraction A). After increasing the NaCl concentration to 0.095 M, a second sharp peak was collected (fraction B). Finally, the third peak (fraction C) was eluted with a 0.29 M NaCl solution (Fig. 5) (of the total protein added to the column, ranging from 30 to 50 mg, 88 ± 4% was recovered after chromatography). As can be seen in Fig. 5, the elution profiles of the three HDL<sub>2</sub> preparations were similar to one another. In terms of cholesterol, the contributions of the three fractions to the total were 49.8 ± 4.1, 44.3 ± 3.2, and 5.9 ± 1.2%, respectively. In terms of protein, the distribution was 47.6 ± 1.0, 44.7 ± 2.6, and 4.8 ± 0.9 for fractions A, B, and C, respectively.

The cholesterol content, apolipoprotein composition, and cholesterol/protein ratio of the HDL<sub>2</sub> subfractions are shown in Table 4. The cholesterol/protein ratio of fractions B and C was higher than that of fraction A. Still, the cholesterol/protein ratio of any HDL<sub>2</sub> fraction was higher than that of HDL<sub>3</sub> (Table 4). The content of free cholesterol versus total cholesterol was the highest for fraction C, intermediate in fraction B, and lowest in fraction A, the differences between them being statistically significant when analyzed by Student's paired *t*-test (Table 4). Free cholesterol content in HDL<sub>3</sub> from the same donors was found to be significantly lower than in total HDL<sub>2</sub> (Table 4).

The apparent molecular weights of the HDL<sub>2</sub> fractions and of HDL<sub>3</sub> were determined by polyacrylamide gradient slab gel electrophoresis. As shown in Fig. 6 (subject KP), it was possible to estimate a mean molecular mass for each fraction relative to the standards. Fraction A presented a mean molecular mass of 300 kDa, while fraction B was slightly higher, about 330 kDa. Fraction C was comprised of two different populations, a major one remaining at the origin of the electrophoresis and a minor population that migrated as a broad band with a mean molecular mass of approximately 530 kDa, clearly higher than those of fractions A and B (Fig. 6). Fraction A presented a tail that overlapped the HDL<sub>3</sub> band. However, the bulk of fraction A presented a mean molecular mass higher and distinguishable from that of HDL<sub>3</sub>, which was 162 kDa (Fig. 6).

The apolipoprotein composition was assessed by SDS polyacrylamide gel electrophoresis and by specific radio-




Fig. 5. Elution profiles of HDL<sub>2</sub> by heparin-Sepharose CL-6B affinity chromatography. Approximately 30–50 mg HDL<sub>2</sub> protein in 0.005 M Tris, pH 7.4, containing 0.05 M NaCl and 0.025 M MnCl<sub>2</sub> was applied to the column (1.0 × 30 cm). The column was operated at 23 ml/h and 3.4-ml fractions were collected. After the unbound lipoproteins were collected (tubes 1–16, fraction A) the buffer was changed to contain 0.095 M NaCl and no MnCl<sub>2</sub> (first arrow). After collecting the second peak (fraction B), the NaCl concentration was increased to 0.29 M (second arrow) to collect the third peak (fraction C). Pooled fractions were dialyzed against buffered 0.15 M NaCl, 1 mM EDTA · Na<sub>2</sub>, pH 7.4.



TABLE 4. Compositional studies of HDL subfractions separated by heparin-Sepharose chromatography

Subject	Fraction	A-I/A-II	E/A-I × 10 <sup>5</sup>	A-I/D	Ch/Prot	% Free Chol
KP	HDL <sub>2</sub>	4.20	36.5	40.6	0.35	26.5
	A	2.78	1.2	37.5	0.31	23.3
	B	5.46	47.9	54.2	0.41	28.1
	C		362.2		0.50	48.2
	HDL <sub>3</sub>	3.76	10.3	10.8	0.19	16.7
CL	HDL <sub>2</sub>	5.13	17.4	50.8	0.37	33.1
	A	3.24	37.4	0.36	0.31	
	B	4.97	8.0	57.7	0.44	36.4
	C		2185.0		0.41	41.3
	HDL <sub>3</sub>	5.25		19.0	0.17	15.7
MAL	HDL <sub>2</sub>	2.80	18.2	38.5	0.42	29.3
	A	2.00	0.3	35.0	0.41	23.2
	B	3.00	12.5	41.3	0.44	29.7
	C		1720.0		0.44	32.5
	HDL <sub>3</sub>	3.00	4.7	16.6	0.20	18.4

Total protein and free and total cholesterol were determined by enzymatic methods, and apoA-I, A-II, E, and D were determined by specific radioimmunoassays (see text for details). Several mass ratios (mg/mg) were calculated for each sample. A, B, and C correspond to the heparin-Sepharose HDL<sub>2</sub> fractions A, B, and C, respectively. The small amounts of fraction C precluded measurement of all apolipoproteins.

immunoassays. Fig. 7 shows the electrophoretic pattern for KPs lipoproteins and the heparin-Sepharose HDL<sub>2</sub> subfractions (the electrophoretic patterns of lipoproteins of the other two donors were similar to that of KP, data not shown). Every HDL<sub>2</sub> subfraction contained apoA-I, apoE, and other minor polypeptides although in different relative proportions (Fig. 7). Fraction C was the richest in apoE and fraction A the poorest. ApoB was also present in fraction C as in total HDL<sub>3</sub>, but not in either fractions A or B (Fig. 6).


To better determine and compare the apolipoprotein composition of HDL<sub>2</sub> subfractions, apolipoproteins A-I, A-II, D, and E were quantitatively measured by radioimmunoassay using specific antibodies. Due to the different albumin content of each lipoprotein preparation, apolipoprotein ratios were calculated (Table 4). As indicated by these ratios, the major apolipoprotein component in fraction A and fraction B as well as in total HDL<sub>2</sub> and HDL<sub>3</sub> was apoA-I. Fraction C of KP revealed apoA-I as the major apolipoprotein, but in CL and MAL, it was apoE. The distinguishing characteristic between the HDL<sub>2</sub> subfractions was their content in apoE as indicated by the ratio apoE/apoA-I. Fraction A was the poorest in apoE, fraction B had an intermediate content, and fraction C was the richest in apoE (Table 4). The content of apoD in total HDL<sub>2</sub> as well as in any HDL<sub>2</sub> subfraction was lower than in HDL<sub>3</sub> as is clearly indicated by the apoA-I/apoD ratios; apoD in fraction C was undetectable (Table 4). It was also found that the relative content of apoA-II in fraction A from each of the subjects was higher than in the respective fraction B, as indicated by the apoA-I/apoA-II ratio (Table 4). ApoA-I/apoA-II ratio in total HDL<sub>2</sub> was found to be similar to that of HDL<sub>3</sub> (Table 4).

#### Role of HDL<sub>2</sub> subfractions of progesterone secretion by the trophoblast

HDL<sub>2</sub> subfractions separated by heparin-Sepharose column chromatography and total HDL<sub>2</sub> and HDL<sub>3</sub> as well as their counterparts modified by cyclohexanedione or reductive methylation were incubated with human trophoblast cells for 24 h as in previous experiments. As controls, the cells were incubated in 10% LPPS containing medium in the absence of lipoprotein cholesterol. The results of progesterone secretion from three separate experiments are shown in Table 5.

In the first experiment (CL in Table 5) the different lipoprotein preparations were added to the cells at the same cholesterol concentration (40 mg/dl). Fraction C was omitted due to its low availability. As in previous experiments, HDL<sub>2</sub> was highly stimulatory whereas HDL<sub>3</sub> did not stimulate any progesterone secretion by the trophoblast. Fraction A hardly stimulated progesterone secretion but fraction B did so significantly (CL in Table 5). Cyclohexanedione modification of the HDL<sub>2</sub> subfractions and total HDL<sub>2</sub> and HDL<sub>3</sub> did not affect the response of the trophoblast to these lipoproteins (CL in Table 5).

In a second experiment (KP in Table 5), HDL<sub>2</sub> subfractions were added at their respective concentrations in 40 mg/dl of total HDL<sub>2</sub> cholesterol, on the hypothesis that their individual effects would add up to equal the total HDL<sub>2</sub> effect. In terms of progesterone secretion, fraction B was still more stimulatory than fraction A, despite being incubated at a slightly lower concentration in the media (KP in Table 5). Fraction C was studied at a very low cholesterol concentration (1.7 mg/dl), nonetheless it clearly stimulated progesterone secretion about fourfold




**Fig. 6.** Polyacrylamide gradient slab gel electrophoresis of heparin-Sepharose HDL<sub>2</sub> fractions, total HDL<sub>2</sub>, and HDL<sub>3</sub>. Electrophoresis was performed on PAA 4/30 polyacrylamide gradient slabs (Pharmacia Fine Chemicals, Uppsala, Sweden). Approximately 15–20  $\mu$ g lipoprotein protein was applied to each well. Reference markers correspond to thyroglobulin, ferritin, catalase, lactate dehydrogenase, and bovine albumin. Electrophoresis was performed in Tris 0.09 M, borate 0.08 M, 0.003 M Na<sub>2</sub>EDTA, pH 8.35, at 125 V for 16 h. The slab was stained with 0.04% Coomassie blue and destained with 7% acetic acid. Lane A is total HDL<sub>2</sub>; lane B is HDL<sub>2</sub>, fraction A; lane C contains standards; lane D is HDL<sub>2</sub>, fraction B; lane E is HDL<sub>2</sub>, fraction C; lane F is total HDL<sub>3</sub>; and lane G is another group of standards.

above control (KP in Table 5). In this experiment the effect of reductive methylation of lipoproteins was tested and no significant difference in progesterone secretion between native and modified HDL<sub>2</sub> subfractions was detected (KP in Table 5).

In a third experiment (MAL in Table 5), fractions A and B and HDL<sub>3</sub> were added to the cells at a cholesterol concentration of 15 mg/dl. Fraction C could be only studied at 1 mg/dl, and total HDL<sub>2</sub> was incubated at both concentrations to facilitate comparison. As can be seen in Table 5 (MAL), fraction B strongly stimulated progesterone secretion, the magnitude of the effect approaching that of total HDL<sub>2</sub> at the same lipoprotein concentration in the medium. In contrast, fraction A showed a lesser effect with progesterone secretion similar to that seen with total HDL<sub>3</sub>. Fraction C significantly stimulated progesterone secretion despite the low cholesterol concentration of 1 mg/dl. Fraction C was nearly 10-fold more effective than total HDL<sub>2</sub> in promoting progesterone secretion (MAL in Table 5). As in the previous experiments, cyclohexanedione modification of the apolipoproteins did not produce any meaningful change in the ability of total HDL<sub>2</sub> or HDL<sub>2</sub> subfractions to stimulate progesterone secretion nor was there any consistent effect on HDL<sub>3</sub> (Table 5).

## DISCUSSION

The production of large amounts of progesterone by the human placenta (1) is sustained by lipoprotein cholesterol (2), as de novo cholesterol synthesis is very limited in this organ (3). While LDL is an established donor of cholesterol to cells (4–7), we previously found that HDL<sub>2</sub> was a potent stimulus for progesterone synthesis and secretion by placental trophoblast cells in culture (9, 10). In the present work we confirm the capacity of HDL<sub>2</sub> to stimulate progesterone secretion. In every experiment, the concentration of progesterone in culture media after a 24-h exposure of trophoblast cells to HDL<sub>2</sub> was higher than in controls (absence of lipoproteins) and of the same order as that observed with LDL<sub>2</sub>. In this respect it is noteworthy that the progesterone response to LDL<sub>2</sub> was variable from one experiment to another depending on the trophoblast preparation (especially in those obtained using trypsin for tissue digestion), while HDL<sub>2</sub> was always highly stimulatory. As progesterone in the lipoprotein additions to media was undetectable for any preparation (unpublished data), medium progesterone was necessarily derived from cultured cells. Since [<sup>14</sup>C]acetate incorporation into cholesterol was depressed in the presence of



**Fig. 7.** SDS polyacrylamide slab gel electrophoresis of delipidated lipoproteins on 10% acrylamide gels. Fifty or 150  $\mu$ g of apolipoprotein (LDL and HDL<sub>2</sub>-fraction C) in 0.01 M phosphate buffer (pH 7.4), 0.2% SDS were reduced with 5% mercaptoethanol. Gels were stained with 0.25% Coomassie brilliant blue and destained. Lane A is LDL; lane B is total HDL; lane C is HDL<sub>2</sub>, fraction A; lane D is HDL<sub>2</sub>, fraction B; lane E is HDL<sub>2</sub>, fraction C; and lane F is total HDL<sub>3</sub>. From top to bottom the major bands are: apoB, albumin, apoE, apoA-I, and apoA-II plus apoC.

TABLE 5. Effects of HDL subfractions separated by heparin-Sepharose chromatography on trophoblast progesterone secretion

Experiment	Native	Cyclohexanedione-Modified	Reductive Methylated
<i>ng progesterone/24 h/100 µg cell protein</i>			
1: Lipoproteins from CL			
Basal	37.5 ± 5.1		
HDL <sub>2</sub> (40 mg/dl)	100.7 ± 0.4	113.5 ± 5.8	
HDL <sub>2</sub> -A (40 mg/dl)	44.4 ± 1.5	34.5 ± 5.3	
HDL <sub>2</sub> -B (40 mg/dl)	86.7 ± 3.8	90.3 ± 10.5	
HDL <sub>3</sub> (40 mg/dl)	26.0 ± 2.8	19.7 ± 2.5	
2: Lipoproteins from KP			
Basal	10.2 ± 7.3		
HDL <sub>2</sub> (40 mg/dl)	103.3 ± 12.5		83.8 ± 7.1
HDL <sub>2</sub> -A (20.4 mg/dl)	60.4 ± 10.0		63.4 ± 5.7
HDL <sub>2</sub> -B (17.9 mg/dl)	80.0 ± 7.6		87.8 ± 12.2
HDL <sub>2</sub> -C (1.7 mg/dl)	37.6 ± 6.2		55.8 ± 12.0
HDL <sub>3</sub> (40 mg/dl)	7.3 ± 6.1		8.0 ± 6.0
3: Lipoproteins from MAL			
Basal	8.6 ± 0.6		
HDL <sub>2</sub> (15 mg/dl)	57.1 ± 3.7	60.4 ± 9.3	
HDL <sub>2</sub> (1 mg/dl)	12.6 ± 3.8	12.5 ± 1.4	
HDL <sub>2</sub> -A (15 mg/dl)	24.4 ± 6.5	24.2 ± 4.3	
HDL <sub>2</sub> -B (15 mg/dl)	47.9 ± 10.2	38.7 ± 10.7	
HDL <sub>2</sub> -C (1 mg/dl)	46.4 ± 7.4	42.8 ± 1.7	
HDL <sub>3</sub> (15 mg/dl)	22.7 ± 7.4	28.1 ± 3.8	

Trophoblast cells (ca. 100 µg cell protein) were incubated in HAM's F-10 medium containing 10% lipoprotein-poor serum for 48 h and then for 24 h in the same medium supplemented with the indicated amount of lipoprotein-cholesterol, and progesterone in medium was determined. Values correspond to the mean ± SE of the triplicate incubations.

HDL<sub>2</sub> as it was for LDL<sub>2</sub> and label derived from HDL-C appeared in cell cholesterol and progesterone, we may assume that HDL<sub>2</sub>-C entered the trophoblast cells and was utilized for progesterone synthesis, as is LDL-C (4, 5).

The uptake of HDL<sub>2</sub>-cholesterol by cells may involve several receptor-dependent and/or receptor-independent mechanisms. ApoE in HDL<sub>2</sub> may facilitate lipoprotein recognition by the B/E receptor (13). ApoA-I could mediate the interaction with the putative HDL-receptor in several cell types (15–19). Free cholesterol transfer from the HDL particle to the cell could take place in the absence of high affinity HDL binding activity (44–46) when a favorable chemical gradient between lipoprotein and cell membrane exists (46–48). In this connection, hepatic lipase and other phospholipases hydrolyze lipoprotein phospholipids and by increasing the free cholesterol/phospholipid mass ratio in HDL, may enhance the uptake of HDL-free cholesterol by different cell types including hepatocytes (49, 50) and granulosa cells (51).

To better understand the mechanisms of lipoprotein cholesterol uptake by trophoblast cells, we first used the tool of chemical modification of apolipoproteins, and compared effects on LDL<sub>2</sub> and HDL<sub>2</sub>. We modified entire lipoproteins by either cyclohexanedione or reductive methylation and, after their addition to the trophoblast cells, found that modified LDL no longer stimulated progesterone secretion as compared to native LDL. This

modification did not block the progesterone secretion induced by HDL<sub>2</sub> despite evidence of apolipoprotein modifications by increased mobility in agarose gel. Concomitantly, [<sup>14</sup>C]acetate incorporation into cell cholesterol, which was significantly depressed in the case of native LDL in comparison to basal incubations, was higher after addition of either arginine- or lysine-modified LDL. No effect of chemical modification of HDL<sub>2</sub> was seen. These results demonstrate that intact apoB-100 is required for LDL to stimulate progesterone secretion and to inhibit cholesterol synthesis from acetate. The HDL<sub>2</sub> stimulation of progesterone secretion is by a different mechanism.

To further explore the role of the LDL receptor, we studied the effect of chloroquine on progesterone secretion. To inhibit lysosomal activity, chloroquine is usually added at a concentration of 100 µM (52) but in preliminary experiments we observed that this high concentration was toxic for the trophoblast in culture (Lasunción, M. A., B. Bonet, and R. H. Knopp, unpublished observations). Therefore, we were obliged to use a lower concentration, 10 µM, in our system. Under these conditions, chloroquine partially inhibited progesterone secretion as a response to LDL without any inherent toxic effect in control experiments, which indicates that lysosomal activity is necessary for LDL processing by the trophoblast cells as in other cells (4). Again, chloroquine had no in-

hibitory effect on HDL<sub>2</sub>-mediated stimulation of progesterone secretion.

Direct evidence of the role of the LDL-receptor in mediating the observed effects of LDL versus HDL<sub>2</sub> was obtained by using monoclonal anti-LDL-receptor antibody. This antibody completely suppressed the effect of LDL stimulating progesterone secretion. To our knowledge, this result is the first direct demonstration of the role of the B/E receptor mediating the uptake of LDL-cholesterol for progesterone synthesis in trophoblast and is in accordance with previous results by others describing the stimulatory effect of LDL on progesterone secretion and the LDL binding activity of trophoblast (5, 6). In contrast, anti-LDL receptor antibody did not block the HDL<sub>2</sub> effect.

To determine whether the HDL<sub>2</sub> effect could be ascribed to any particular subfraction, especially to apoE-rich particles, we used heparin-Sepharose column chromatography to separate three different HDL<sub>2</sub> subpopulations. The elution profile of HDL<sub>2</sub> from normolipidemic subjects observed was similar to that described previously by others in human subjects (31, 53) with the exception that in the present work the fraction that eluted at 0.095 M NaCl was the majority, which is probably due to the use of a commercial heparin-Sepharose CL-6B resin instead of a heparin-Sepharose CL-4B prepared from the CNBr-activated form (31). The affinity of the fractions to heparin was correlated with their content of apoE as fraction A (unbound) was the poorest and fraction C the richest in apoE. Fraction C was formed by two different lipoprotein populations as indicated by polyacrylamide gradient gel electrophoresis. Weisgraber and Mahley (31) found that the "bound-II fraction" (equivalent to fraction C herein) was a homogeneous population in terms of apparent molecular mass, with apoB as the sole apolipoprotein, and they concluded that this fraction corresponded to LDL and/or Lp[a] contamination in the HDL<sub>2</sub> density range (31). We also found electrophoretic evidence of apoB, but also detected a smaller amount of apoE and apoA-I in fraction C. Lipid composition of HDL<sub>2</sub> subclasses and HDL<sub>3</sub> was also different. As indicated by the total cholesterol/protein ratio and by the % of free versus total cholesterol, fraction C was richest in free cholesterol and HDL<sub>3</sub> was poorest in free cholesterol.

On incubating these HDL<sub>2</sub> fractions with trophoblast cells, we found that fraction B stimulated more progesterone secretion than fraction A. In fact, except for one preparation, fraction A hardly stimulated progesterone secretion in comparison with HDL<sub>3</sub> or lipoprotein-poor serum (control). When fraction C was studied, we found that its stimulation of progesterone secretion was several times greater than total HDL<sub>2</sub> at the same cholesterol concentration in the media. HDL<sub>2</sub> fraction C was also relatively more effective than fraction B if the different concentrations used are considered. Because of the abun-

dance of apoE in HDL<sub>2</sub> fraction C and the possibility of apoB contamination, we again treated the subfractions with cyclohexanedione or reductive methylation and again found no inhibition of the stimulatory effects of these subfractions on progesterone secretion. These results indicate that the ability of HDL<sub>2</sub> subfractions to deliver cholesterol to the trophoblast cell does not depend upon intact apoE. While apoE-containing HDL<sub>2</sub> could eventually be recognized and taken up by the B/E receptor in their native form, other mechanisms must be involved in the delivery of cholesterol from these lipoproteins to cells in order to explain our observations.

A high affinity binding activity for apoE-free HDL, which recognizes apoA-I, has been reported in many human cell types (15, 16, 18, 19, 54–56). Very recently a protein has also been purified from human placental membrane preparations that binds apoA-I with high affinity (23, 57). This putative HDL receptor has been implicated in the efflux rather than the influx of cholesterol to the cells (18, 19) and it has been suggested that binding of HDL to the cell membrane facilitates sterol translocation between intracellular and plasma membrane pools which allows the transfer of free cholesterol to the HDL particle (17, 44, 55). However, this latter process is known to be independent of HDL binding to the cell (22, 45, 55). To determine whether the effects of HDL<sub>2</sub> and HDL<sub>3</sub> on the trophoblast cells were mediated by the putative HDL receptor, we modified these lipoproteins by treatment with either TNM or DMS. The concentrations of the chemicals and the conditions used were those reported to inhibit HDL binding to cells maximally (28, 30). Confirmation of the extent of the HDL<sub>2</sub> and HDL<sub>3</sub> modification was obtained from nondenaturing polyacrylamide gradient gel electrophoresis and from agarose electrophoresis. When these TNM- or DMS-modified HDL<sub>2</sub> were added to the trophoblast cells, progesterone concentration in the media increased to the same level as with native HDL. HDL<sub>3</sub> were only modified with TNM and these lipoproteins behaved as the native ones, namely, they did not stimulate progesterone secretion as compared to controls even when they were added at a cholesterol concentration in the medium of 20 mg/dl. This inability of HDL<sub>3</sub> to stimulate progesterone secretion was previously observed by Winkel et al. (5), despite the fact that these lipoproteins bind specifically to trophoblast membranes (6). Therefore, present results indicate that HDL effects on trophoblast cells are not mediated by lipoprotein binding to the surface membrane and agree with recent results by others demonstrating that the flux of cholesterol between HDL and fibroblast is independent of apoA-I binding (44, 58) and is not affected by inhibition of HDL binding (45, 46).

There is controversy about the mechanisms for HDL uptake in other steroidogenic cells. In rat corpus luteum cells it was observed that pronase virtually abolished their

capacity to bind  $^{125}\text{I}$ -labeled HDL and made them unable to increase progesterone secretion from added HDL (59). However, rat ovarian cell steroidogenesis has been observed by others to be supported by either native or modified HDL, suggesting that HDL can deliver its sterols through low affinity cellular associations (60, 61). A number of recent studies in the rat have reached the conclusion that a large part of the internalized HDL cholesterol occurs via a receptor-independent pathway (12, 58, 62). Our results are in accordance with these observations and suggest that the uptake of free or esterified cholesterol from HDL<sub>2</sub> by the trophoblast cells takes place through a receptor-independent pathway.

In the absence of a demonstrable role for apoE, the factor responsible for the observed differences in the ability of HDL<sub>2</sub> subfractions to support placental steroidogenesis seems to be the free cholesterol content of these lipoproteins. In fact, fraction C had the highest percentage of free cholesterol; fraction B had an intermediate value; and fraction A had the lowest value among the HDL<sub>2</sub> subfractions. If expressed as the free cholesterol/apolipoprotein mass ratio, the differences are even more accentuated. Interestingly, total HDL<sub>3</sub> had a free cholesterol content clearly lower than any HDL<sub>2</sub> fraction. Therefore, it is possible that the free cholesterol content of the HDL particle is related to its effect on progesterone secretion.

The interchange of free cholesterol between lipoproteins and cells has been demonstrated to occur with different cell types and with native as well as apolipoprotein/lipid vesicles (47, 63, 64) and the net movement of this sterol in one or the opposite direction occurs by passive, mass action effects (46). In 1978, Rothblat, Arbogast, and Ray (65) found that HDL enriched in free cholesterol produced sterol accumulation in hepatoma cells and O'Malley, Soltys, and Portman (66) observed that the influx of free cholesterol from HDL to hepatocytes was greater than that from LDL. It was also found that the movement of free cholesterol was not correlated to lipoprotein internalization and degradation (20, 65, 66). Finally, recent studies by others have given evidence that steroidogenic cells preferentially use HDL free cholesterol rather than esterified cholesterol for progesterone synthesis (51, 60, 67) and that free cholesterol is taken up by a receptor-independent pathway (67). Consistent with these observations, our results point to the passive transfer of free cholesterol from a small lipoprotein fraction particularly rich in free cholesterol to the cell membrane, by a process that does not involve the LDL receptor or even the binding of HDL apolipoproteins to the cell. The transfer of a minor part of lipoprotein free cholesterol seems sufficient for supporting progesterone synthesis in the trophoblast in culture as, in an average incubation with total HDL<sub>2</sub>, the mass of progesterone secreted is just 1/1000 of the mass of lipoprotein free cholesterol. Therefore, it may be envisioned that in this system there is a chemical gra-

dient of free cholesterol between HDL<sub>2</sub> and the intracellular trophoblast pool that allows net influx into the cell, probably by aqueous diffusion (46, 47). Further research is required to evaluate this hypothesis.

In conclusion, we have confirmed that LDL cholesterol is taken up by trophoblast cells mainly or solely through the B/E receptor, while HDL<sub>2</sub> cholesterol is taken up by a receptor-independent mechanism. The relative physiological importance of LDL versus HDL for the delivery of lipoprotein cholesterol for placental steroidogenesis remains to be elucidated. Nonetheless, in pregnancies carrying fetuses homozygous for familial hypercholesterolemia where the placenta is an obligate homozygote for the defective LDL receptor or in maternal hypobetalipoproteinemia where pregnancies are also viable (68), HDL may provide a reserve or alternative supply of cholesterol to the placenta for progesterone synthesis and transport to the fetus to support fetal growth and development. ■

The authors thank Dr. Marian Cheung and Dr. John Albers for radioimmunoassays, Dr. Alan Chait for the monoclonal anti-LDL receptor antibody, and Drs. James Humphrey, Job R. Li, and Craig McAllister and Mr. Robert Lawson who contributed to the early stages of this project. This research was supported by the U.S.-Spain Joint Commission for Scientific and Technological Cooperation, CCA8510-061, the Clinical Nutrition Research Unit (CNRU) at the University of Washington, DK-35816, and a gift from the Ortho Pharmaceutical Company.

Manuscript received 16 October 1989 and in revised form 9 April 1991.

## REFERENCES

1. Knopp, R. H., A. Montes, M. Childs, J. R. Li, and H. Mabuchi. 1981. Metabolic adjustments in normal and diabetic pregnancy. *Clin. Obstet. Gynecol.* **24**: 21-49.
2. Hellig, H., D. Gottereau, Y. Celebyre, and E. Bolte. 1970. Steroid production from plasma cholesterol. I. Conversion of plasma cholesterol to placental progesterone in humans. *J. Clin. Endocrinol. Metab.* **30**: 624-631.
3. Van Leusden, H., and C. A. Villee. 1965. The de novo synthesis of sterols and steroids from acetate by preparations of human term placenta. *Steroids.* **6**: 31-45.
4. Goldstein, J. L., and M. C. Brown. 1977. The low density lipoprotein pathway and its relation to atherosclerosis. *Annu. Rev. Biochem.* **46**: 897-930.
5. Winkel, C. A., J. M. Snyder, P. C. MacDonald, and E. R. Simpson. 1980. Regulation of cholesterol and progesterone synthesis in human placental cells in culture by serum lipoproteins. *Endocrinology.* **106**: 1054-1060.
6. Winkel, C. A., J. Gilmore, P. C. MacDonald, and E. R. Simpson. 1980. Uptake and degradation of lipoproteins by human trophoblastic cells in primary culture. *Endocrinology.* **107**: 1892-1898.
7. Winkel, C. A., P. C. MacDonald, P. G. Hensell, and E. R. Simpson. 1981. Regulation of cholesterol metabolism by human trophoblastic cells in primary culture. *Endocrinology.* **109**: 1084-1090.
8. Cummings, S. W., W. Heatley, E. R. Simpson, and M. Ohashi. 1982. The binding of high and low density lipoproteins to human placental membrane fractions. *J. Clin. Endocrinol. Metab.* **54**: 903-908.

9. Knopp, R. H., R. Lawson, and J. R. Li. 1981. Effect of high density lipoprotein on progesterone secretions by cultured placental cells. *Circulation*. **65**: (Part II, IV) 271 (abstract).
10. Knopp, R. H., and R. Lawson. 1982. Effects of intracellular cholesterol depletion on human trophoblast progesterone secretion and the response to low and high density lipoprotein. Program of the 64th Annual Meeting of the Endocrine Society, San Francisco, CA (Abstract 389).
11. Oram, J. F., J. J. Albers, M. C. Cheung, and E. L. Bierman. 1981. The effects of subfractions of high density lipoproteins on cholesterol efflux from cultured fibroblasts. Regulation of low density lipoprotein receptor activity. *J. Biol. Chem.* **256**: 8348-8356.
12. Lietersdorf, E., O. Stein, S. Eisenberg, and Y. Stein. 1984. Uptake of rat plasma HDL subfractions labelled with [<sup>3</sup>H]cholesteryl linoleyl ether or with <sup>125</sup>I by cultured rat hepatocytes and adrenal cells. *Biochim. Biophys. Acta.* **796**: 72-82.
13. Mahley, R. W., T. L. Innerarity, R. E. Pitas, K. H. Weisgraber, J. H. Brown, and E. Gross. 1977. Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins. *J. Biol. Chem.* **252**: 7279-7287.
14. Hui, D. Y., T. L. Innerarity, and R. W. Mahley. 1981. Lipoprotein binding to canine hepatic membranes. Metabolically distinct apoE and apoB,E receptors. *J. Biol. Chem.* **256**: 5646-5655.
15. Biesbroeck, R., J. F. Oram, J. J. Albers, and E. L. Bierman. 1983. Specific high affinity binding of high density lipoproteins to cultured human fibroblasts and arterial smooth muscle cells. *J. Clin. Invest.* **71**: 525-539.
16. Brinton, E. A., J. F. Oram, C-H. Chen, J. J. Albers, and E. L. Bierman. 1986. Binding of high density lipoprotein to cultured fibroblast after chemical modification of apoprotein amino acid residues. *J. Biol. Chem.* **261**: 495-503.
17. Aviram, M., E. L. Bierman, and J. F. Oram. 1989. High density lipoprotein stimulates sterol translocation between intracellular and plasma membrane pools in human monocyte-derived macrophages. *J. Lipid Res.* **30**: 65-76.
18. Brinton, E. A., R. D. Kenagy, J. F. Oram, and E. L. Bierman. 1985. Regulation of high density lipoprotein binding activity to aortic endothelial cells by treatment with acetylated low density lipoprotein. *Arteriosclerosis*. **5**: 329-335.
19. Schmitz, G., R. Niemann, B. Brennhäusen, R. Krause, and G. Assmann. 1985. Regulation of high density lipoprotein receptors in cultured macrophages: role of acyl-CoA:cholesterol acyltransferase. *EMBO J.* **4**: 2773-2779.
20. Wu, J-D., J. Butler, and J. M. Bailey. 1979. Lipid metabolism in cultured cells. XVIII. Comparative uptake of low density and high density lipoproteins by normal, hypercholesterolemic and tumor virus-transformed human fibroblasts. *J. Lipid Res.* **20**: 472-480.
21. Tabas, I., and A. R. Tall. 1984. Mechanism of the association of HDL<sub>3</sub> with endothelial cells, smooth muscle cells, and fibroblasts. *J. Biol. Chem.* **259**: 13897-13905.
22. Mendel, C. M., S. T. Kunitake, J. P. Kane, and E. S. Kempner. 1988. Radiation inactivation of binding sites for high density lipoproteins in human fibroblast membranes. *J. Biol. Chem.* **263**: 1314-1319.
23. Graham, D. L., and J. F. Oram. 1987. Characterization of a high density lipoprotein-binding protein in cell membranes by ligand blotting. *J. Biol. Chem.* **262**: 7439-7442.
24. Havel, R. J., H. Eder, and J. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally reported lipoproteins in human serum. *J. Clin. Invest.* **34**: 1345-1353.
25. Steinberg, D., P. J. Nestel, D. B. Weinstein, M. Remant-Desmeth, and C. M. Chang. 1978. Interactions of native and modified human low density lipoproteins with human skin fibroblasts. *Biochim. Biophys. Acta.* **528**: 199-212.
26. Oram, J. F., J. J. Albers, and E. L. Bierman. 1980. Rapid regulation of the activity of the low density lipoprotein receptor of cultured human fibroblasts. *J. Biol. Chem.* **255**: 475-485.
27. Weisgraber, K. H., T. L. Innerarity, and R. W. Mahley. 1978. Role of the lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. *J. Biol. Chem.* **253**: 9053-9062.
28. Chacko, G. K. 1985. Modification of human high density lipoprotein (HDL<sub>3</sub>) with tetranitromethane and the effect on its binding to isolated rat liver plasma membranes. *J. Lipid Res.* **26**: 745-754.
29. Chacko, G. K., S. Lund-Katz, W. J. Johnson, and J. B. Karlin. 1987. Tetranitromethane modification of human high density lipoprotein (HDL<sub>3</sub>): inactivation of high density lipoprotein binding is not related to cross-linking of phospholipids to apoproteins. *J. Lipid Res.* **28**: 332-337.
30. Chacko, G. K., F. H. Mahlberg, and W. J. Johnson. 1988. Cross-linking of apoproteins in high density lipoprotein by dimethylsuberimidate inhibits specific lipoprotein binding to membranes. *J. Lipid Res.* **29**: 319-324.
31. Weisgraber, K. H., and R. W. Mahley. 1980. Subfractionation of human high density lipoproteins by heparin-Sepharose affinity chromatography. *J. Lipid Res.* **21**: 316-325.
32. Hara, A., and N. S. Radin. 1978. Lipid extraction of tissues with a low-toxicity solvent. *Anal. Biochem.* **90**: 420-426.
33. Skipski, V. P., and M. Barclay. 1969. Thin-layer chromatography of lipids. *Methods Enzymol.* **14**: 530-598.
34. Folch, J., M. Lees, and G. M. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipids from animal tissues. *J. Biol. Chem.* **226**: 497-503.
35. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* **193**: 265-275.
36. Kerpel, S. H., E. Shafir, and B. Shapiro. 1961. Mechanism of fatty acid assimilation in adipose tissue. *Biochim. Biophys. Acta.* **46**: 495-504.
37. Parekh, A. C., M. Caranto, R. K. Mathur, D. H. Jung. 1976. Fractionation of cholesterol, a critique. *Ann. Clin. Lab. Sci.* **6**: 423-429.
38. Heider, J. G., and R. L. Boyett. 1978. The picomole determination of free and total cholesterol in cells in culture. *J. Lipid Res.* **19**: 514-518.
39. Weber, K., and M. Osborn. 1969. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. *J. Biol. Chem.* **244**: 4406-4412.
40. Albers, J. J., P. W. Wahl, V. G. Cabana, W. R. Hazzard, and J. J. Hoover. 1976. Quantification of apolipoprotein A-I of human plasma high density lipoprotein. *Metabolism.* **25**: 633-644.
41. Cheung, M. C., and J. J. Albers. 1977. The measurement of apolipoprotein A-I and A-II levels in men and women by immunoassay. *J. Clin. Invest.* **60**: 43-50.
42. Albers, J. J., M. C. Cheung, S. L. Emers, and J. H. Tollefson. 1981. Characterization and immunoassay of lipoprotein D. *Atherosclerosis.* **39**: 395-409.

43. Tan, M. H., P. D. T. Dickerson, J. J. Albers, R. J. Havel, M. C. Cheung, and J. L. Vigne. 1986. The effect of a high cholesterol and saturated fat diet on serum high-density lipoprotein cholesterol apoprotein A-I, and apoprotein E levels in normolipidemic humans. *Am. J. Clin. Nutr.* **33**: 2559-2565.
44. Picardo, M., J. B. Massey, D. E. Kuhn, A. M. Gotto, S. H. Gianturco, and H. J. Pownall. 1986. Partially reassembled high density lipoproteins. Effects on cholesterol flux, synthesis, and esterification in normal human skin fibroblasts. *Arteriosclerosis*. **6**: 434-441.
45. Karlin, J. B., W. J. Johnson, C. R. Benedict, G. K. Chacko, M. C. Phillips, and G. R. Rothblat. 1987. Cholesterol flux between cells and high density lipoprotein. Lack of relationship to specific binding of the lipoprotein to the cell surface. *J. Biol. Chem.* **262**: 12557-12564.
46. Johnson, W. J., F. H. Mahlberg, G. K. Chacko, M. C. Phillips, and G. H. Rothblat. 1988. The influence of cellular and lipoprotein cholesterol contents on the flux of cholesterol between fibroblasts and high density lipoprotein. *J. Biol. Chem.* **263**: 14099-14106.
47. Rothblat, G. H., and M. C. Phillips. 1982. Mechanism of cholesterol efflux from cells. Effects of acceptor structure and concentration. *J. Biol. Chem.* **257**: 4775-4782.
48. Phillips, M. C., and G. H. Rothblat. 1987. Cholesterol flux between high-density lipoproteins and cells. *Atheroscler. Rev.* **16**: 57-86.
49. Bamberger, M., J. M. Glick, and G. R. Rothblat. 1983. Hepatic lipase stimulates the uptake of high density lipoprotein cholesterol by hepatoma cells. *J. Lipid Res.* **24**: 869-876.
50. Bamberger, M., S. Lund-Katz, M. C. Phillips, and G. H. Rothblat. 1985. Mechanism of the hepatic lipase-induced accumulation of high-density lipoprotein cholesterol by cells in culture. *Biochemistry*. **24**: 3693-3701.
51. Parinaud, J., B. Perret, H. Ribbes, H. Chap, G. Pontonnier, and L. Douste-Blazy. 1987. High density lipoprotein and low density lipoprotein utilization by human granulosa cells for progesterone synthesis in serum-free culture: respective contributions of free and esterified cholesterol. *J. Clin. Endocrinol. Metab.* **64**: 409-417.
52. Brown, M. S., S. E. Dana, and J. L. Goldstein. 1975. Receptor-dependent hydrolysis of cholesteryl esters contained in plasma low density lipoprotein. *Proc. Natl. Acad. Sci. USA.* **72**: 2925-2929.
53. Quarfordt, S. H., R. S. Jain, L. Jakor, S. Robinson, and F. A. Shelburne. 1978. The heterogeneity of rat high density lipoproteins. *Biochem. Biophys. Res. Commun.* **83**: 786-793.
54. Oram, J. F., E. H. Brinton, and E. L. Bierman. 1983. Regulation of high density lipoprotein receptor activity in cultured human skin fibroblasts and human arterial smooth muscle cells. *J. Clin. Invest.* **72**: 1611-1621.
55. Slotte, J. P., J. F. Oram, and E. L. Bierman. 1987. Binding of high density lipoproteins to cell receptors promotes translocation of cholesterol from intracellular membranes to the cell surface. *J. Biol. Chem.* **262**: 12904-12907.
56. Schmitz, G., H. Robenek, U. Lohmann, and G. Assmann. 1985. Interaction of high density lipoproteins with cholesteryl ester-laden macrophages: biochemical and morphological characterization of cell surface receptor binding, endocytosis and resecretion of high density lipoproteins by macrophages. *EMBO J.* **4**: 613-622.
57. Ehnholm, C., M. Tozuka, M. Lukka, and N. Fidge. 1989. Characterization of an HDL binding protein in human placenta. Eighth International Symposium on Atherosclerosis, Rome. Abstract book: 226.
58. Glass, C., R. C. Pittman, D. B. Weinstein, and D. Steinberg. 1983. Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal and gonad. *Proc. Natl. Acad. Sci. USA.* **80**: 5435-5439.
59. Aitken, J. W., R. Booth, and D. A. Stansfield. 1988. Luteal progesterone synthesis and high-density lipoprotein. Evidence implicating a pronase-sensitive HDL-binding site in the mechanism by which HDL supports luteal progesterone synthesis. *Eur. J. Biochem.* **171**, 279-284.
60. Nestler, J. E., M. Bamberger, G. H. Rothblat, and J. F. Strauss III. 1985. Metabolism of high density lipoproteins reconstituted with [<sup>3</sup>H]cholesteryl ester and [<sup>14</sup>C]cholesterol in the rat, with special reference to the ovary. *Endocrinology*. **117**: 502-510.
61. Nestler, J. E., G. K. Chacko, and J. F. Strauss III. 1985. Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetranitromethane. *J. Biol. Chem.* **260**: 7316-7321.
62. Pittman, R. C., T. P. Knecht, M. Rosenbaum, and C. L. Taylor, Jr. 1987. A nonendocytotic mechanism for the selective uptake of high density lipoprotein-associated cholesterol esters. *J. Biol. Chem.* **262**: 2443-2450.
63. Angel, A., R. Yuen, and J. A. Nettleton. 1981. Exchange of free cholesterol between low density lipoproteins and human adipocytes. *Can. J. Biochem.* **59**: 655-661.
64. Slotte, J. P., A. Chait, and E. L. Bierman. 1988. Cholesterol accumulation in aortic smooth muscle cells exposed to low density lipoproteins. Contribution of free cholesterol transfer. *Arteriosclerosis*. **8**: 750-758.
65. Rothblat, G. H., L. Y. Arbogast, and E. K. Ray. 1978. Stimulation of esterified cholesterol accumulation in tissue culture cells exposed to high density lipoproteins enriched in free cholesterol. *J. Lipid Res.* **19**: 350-358.
66. O'Malley, J. P., P. A. Soltys, and O. W. Portman. 1981. Interaction of free cholesterol and apoproteins of low and high density lipoproteins with isolated rabbit hepatocytes. *J. Lipid Res.* **22**: 1214-1224.
67. Rajan, V. P., and K. M. J. Menon. 1988. Differential uptake and metabolism of free and esterified cholesterol from high-density lipoproteins in the ovary. *Biochim. Biophys. Acta.* **959**: 206-213.
68. Parker, C. R., Jr., D. R. Illingworth, J. Bissonnette, and B. R. Carr. 1986. Endocrine changes during pregnancy in a patient with homozygous familial hypobetalipoproteinemia. *N. Engl. J. Med.* **314**: 557-568.